| 000 | 01721cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030806.0 | ||
| 008 | 130312s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2012.Ib.P | ||
| 100 | 0 | _aIbrahim Ahmed Elsaid Mohamed | |
| 245 | 1 | 2 |
_aA pharmaceutical study on controlled release baclofen tablets / _cIbrahim A. Elsaid ; Supervised Omaima N. Elgazayerly , Rawia M. Khalil , Ahmed A. Aboelwafa |
| 246 | 1 | 5 | _aدراسة صيدلية على أقراص منضبطة الإنطلاق لعقار الباكلوفين |
| 260 |
_aCairo : _bIbrahim Ahmed Elsaid Mohamed , _c2012 |
||
| 300 |
_a245P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aThe main goal of this work is to formulate gastroretentive dosage forms capable of increasing the residence of baclofen at its absorption window and modifying oral baclofen release , in an attempt to counteract the low plasma elimination half - life of baclofen (3 to 4 hours) , minimize dose fluctuation and improve therapeutic response for patients suffering from spasticity and chronic musculoskeletal conditions | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBaclofen | |
| 653 | 4 | _aGastroretentive | |
| 653 | 4 | _aSuperporous | |
| 700 | 0 |
_aAhmed Abdelfatah Aboelwafa , _eSupervisor |
|
| 700 | 0 |
_aOmaima Naeem Elgazayerly , _eSupervisor |
|
| 700 | 0 |
_aRawia Mohamed Khalil , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c42019 _d42019 |
||